458,527 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 458,527 shares of the medical research company's stock, valued at approximately $33,945,000. Edwards Lifesciences makes up about 0.5% of Susquehanna Fundamental Investments LLC's investment portfolio, making the stock its 27th largest holding. Susquehanna Fundamental Investments LLC owned 0.08% of Edwards Lifesciences at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $3,173,000. World Investment Advisors LLC boosted its holdings in Edwards Lifesciences by 1,660.7% in the third quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock worth $4,770,000 after acquiring an additional 68,172 shares in the last quarter. Wilmington Savings Fund Society FSB boosted its holdings in Edwards Lifesciences by 147.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock worth $601,000 after acquiring an additional 5,420 shares in the last quarter. Destination Wealth Management boosted its holdings in Edwards Lifesciences by 2.8% in the third quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock worth $463,000 after acquiring an additional 193 shares in the last quarter. Finally, Tidal Investments LLC boosted its holdings in Edwards Lifesciences by 0.7% in the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock worth $2,609,000 after acquiring an additional 275 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research report on Friday, April 25th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, Piper Sandler upgraded shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their price target for the company from $73.00 to $80.00 in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Trading Up 0.3 %

Shares of Edwards Lifesciences stock traded up $0.26 during trading on Thursday, reaching $75.75. 1,103,533 shares of the stock were exchanged, compared to its average volume of 4,717,312. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock's fifty day moving average is $71.03 and its 200 day moving average is $71.23. The firm has a market cap of $44.53 billion, a price-to-earnings ratio of 10.87, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the firm earned $0.66 earnings per share. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock valued at $5,163,062 over the last three months. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.